Literature DB >> 4074607

Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients.

J H Silas, S Freestone, M S Lennard, L E Ramsay.   

Abstract

We have compared the beta-adrenoceptor blocking and antihypertensive effects of chronic once daily treatment with conventional metoprolol 200 mg, two 'long-acting' formulations of metoprolol 200 mg and atenolol 100 mg in a cross-over study in 12 hypertensive patients concurrently receiving diuretic therapy. The peak effects of all compounds were similar, with significant reductions in exercise heart rate and blood pressure. Twenty-four hours after dosing only atenolol treatment was consistently associated with a reduction in both exercise heart rate (P less than 0.001) and blood pressure (P less than 0.02) when compared with placebo. Once daily treatment of hypertension with metoprolol, even in 'long-acting' formulations, cannot be recommended because of waning antihypertensive effect which would be missed at routine clinic attendance. Metoprolol should be prescribed twice daily in hypertension. So-called long-acting formulations do not always confer benefits over conventional dose forms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4074607      PMCID: PMC1400893          DOI: 10.1111/j.1365-2125.1985.tb05082.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Atenolol and metoprolol in mild hypertension.

Authors:  T A Jeffers; J Webster; B Reid; J C Petrie; N P Barker
Journal:  Br Med J       Date:  1978-11-04

3.  Beta-blockers: once or three times a day?

Authors:  T Reybrouck; A Amery; R Fagard; P Jousten; P Lijnen; E Meulepas
Journal:  Br Med J       Date:  1978-05-27

4.  Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.

Authors:  C P Quaterman; M J Kendall; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

5.  Effect on intra-arterial blood pressure of slow release metoprolol combined with placebo or chlorthalidone.

Authors:  H A Kieso; B A Gould; S Mann; R S Hornung; D G Altman; E B Raftery
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-10

6.  Clinical evaluation of Dinamap 845 automated blood pressure recorder.

Authors:  J H Silas; A T Barker; L E Ramsay
Journal:  Br Heart J       Date:  1980-02

7.  Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.

Authors:  W J Leahey; J D Neill; M P Varma; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

8.  Once-daily metoprolol in primary hypertension.

Authors:  B E Karlberg; O Nilsson; K Tolagen; E Nitelius; U Waern
Journal:  Clin Pharmacol Ther       Date:  1979-04       Impact factor: 6.875

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.

Authors:  A Bobik; G L Jennings; P I Korner; P Ashley; G Jackman
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

View more
  11 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

2.  Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.

Authors:  R V Lewis; L E Ramsay; P R Jackson; W W Yeo; M S Lennard; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

3.  Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.

Authors:  N D Eddington; P Marroum; R Uppoor; A Hussain; L Augsburger
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 4.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study.

Authors:  Donald Redelmeier; Damon Scales; Alexander Kopp
Journal:  BMJ       Date:  2005-10-06

Review 6.  Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.

Authors:  Y W Lam; A M Shepherd
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

7.  Design of a new multiple-unit controlled-release formulation of metoprolol--metoprolol CR.

Authors:  A Sandberg; G Ragnarsson; U E Jonsson; J Sjögren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing.

Authors:  A Sandberg; B Abrahamsson; A Svenheden; B Olofsson; R Bergstrand
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

Review 9.  Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.

Authors:  M J Kendall; S R Maxwell; A Sandberg; G Westergren
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

10.  Exercise metabolism in healthy volunteers taking atenolol, high and low doses of metoprolol CR/Z0K, and placebo.

Authors:  A Head; S Maxwell; M J Kendall; C Eagles
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.